Cargando…
Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
Tenofovir disoproxil fumarate (TDF) is thought to cause varying degrees of hypophosphatemia in patients with chronic hepatitis B (CHB). Therefore, we investigated factors that cause hypophosphatemia in patients treated with TDF and methods to increase serum phosphorus concentrations in clinical prac...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922420/ https://www.ncbi.nlm.nih.gov/pubmed/31852136 http://dx.doi.org/10.1097/MD.0000000000018351 |
_version_ | 1783481335038345216 |
---|---|
author | Lee, Dohyeong Yun, Byung Cheol Seo, Kwang Il Han, Byung Hoon Lee, Sang Uk Park, Eun Taek Lee, Jin Wook Jeong, Joonho |
author_facet | Lee, Dohyeong Yun, Byung Cheol Seo, Kwang Il Han, Byung Hoon Lee, Sang Uk Park, Eun Taek Lee, Jin Wook Jeong, Joonho |
author_sort | Lee, Dohyeong |
collection | PubMed |
description | Tenofovir disoproxil fumarate (TDF) is thought to cause varying degrees of hypophosphatemia in patients with chronic hepatitis B (CHB). Therefore, we investigated factors that cause hypophosphatemia in patients treated with TDF and methods to increase serum phosphorus concentrations in clinical practice. We completed a retrospective review of patients with CHB treated with TDF initially at Kosin University Gospel Hospital, Busan, Korea from January 2012 to January 2017. Subclinical hypophosphatemia and hypophosphatemia were defined as serum phosphorus below 3.0 mg/dL and 2.5 mg/dL, respectively. We screened 206 patients with CHB treated with TDF, among which 135 were excluded for the following reasons: baseline malignancy (59), limited data (50), co-administered other antivirals (14), hypophosphatemia at baseline (7), and other reasons (5). The final study population comprised 71 patients. Subclinical hypophosphatemia developed in 43 (60.5%) patients. Hypophosphatemia occurred in 18 patients (25.3%). Liver cirrhosis was the most significant predictor of hypophosphatemia (P = .038, OR = 3.440, CI = 1.082–10.937) Patients diagnosed with subclinical hypophosphatemia were encouraged to increase their intake of nuts and dairy products (25 patients) or reduce their alcohol intake (2), dose reduction of TDF (4) or placed under observation (4). Among patients with subclinical hypophosphatemia, serum phosphorus concentrations were elevated (>3.0 mg/dL) in 23 of 36 patients (63.8%). Increased nut and dairy intake increased phosphorus concentrations to more than 3.0 mg/dl in 16 of 25 patients (64.0%). Entecavir or tenofovir alafenamide fumarate (TAF) should be considered rather than TDF in patients with liver cirrhosis because of the risk of hypophosphatemia. Instead of stopping TDF treatment, encouraging increased intake of phosphorus-rich foods could increase serum phosphorus concentrations in clinical practice. |
format | Online Article Text |
id | pubmed-6922420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-69224202020-01-23 Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate Lee, Dohyeong Yun, Byung Cheol Seo, Kwang Il Han, Byung Hoon Lee, Sang Uk Park, Eun Taek Lee, Jin Wook Jeong, Joonho Medicine (Baltimore) 4500 Tenofovir disoproxil fumarate (TDF) is thought to cause varying degrees of hypophosphatemia in patients with chronic hepatitis B (CHB). Therefore, we investigated factors that cause hypophosphatemia in patients treated with TDF and methods to increase serum phosphorus concentrations in clinical practice. We completed a retrospective review of patients with CHB treated with TDF initially at Kosin University Gospel Hospital, Busan, Korea from January 2012 to January 2017. Subclinical hypophosphatemia and hypophosphatemia were defined as serum phosphorus below 3.0 mg/dL and 2.5 mg/dL, respectively. We screened 206 patients with CHB treated with TDF, among which 135 were excluded for the following reasons: baseline malignancy (59), limited data (50), co-administered other antivirals (14), hypophosphatemia at baseline (7), and other reasons (5). The final study population comprised 71 patients. Subclinical hypophosphatemia developed in 43 (60.5%) patients. Hypophosphatemia occurred in 18 patients (25.3%). Liver cirrhosis was the most significant predictor of hypophosphatemia (P = .038, OR = 3.440, CI = 1.082–10.937) Patients diagnosed with subclinical hypophosphatemia were encouraged to increase their intake of nuts and dairy products (25 patients) or reduce their alcohol intake (2), dose reduction of TDF (4) or placed under observation (4). Among patients with subclinical hypophosphatemia, serum phosphorus concentrations were elevated (>3.0 mg/dL) in 23 of 36 patients (63.8%). Increased nut and dairy intake increased phosphorus concentrations to more than 3.0 mg/dl in 16 of 25 patients (64.0%). Entecavir or tenofovir alafenamide fumarate (TAF) should be considered rather than TDF in patients with liver cirrhosis because of the risk of hypophosphatemia. Instead of stopping TDF treatment, encouraging increased intake of phosphorus-rich foods could increase serum phosphorus concentrations in clinical practice. Wolters Kluwer Health 2019-12-16 /pmc/articles/PMC6922420/ /pubmed/31852136 http://dx.doi.org/10.1097/MD.0000000000018351 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 4500 Lee, Dohyeong Yun, Byung Cheol Seo, Kwang Il Han, Byung Hoon Lee, Sang Uk Park, Eun Taek Lee, Jin Wook Jeong, Joonho Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate |
title | Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate |
title_full | Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate |
title_fullStr | Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate |
title_full_unstemmed | Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate |
title_short | Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate |
title_sort | risk factors associated with hypophosphatemia in chronic hepatitis b patients treated with tenofovir disoproxil fumarate |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922420/ https://www.ncbi.nlm.nih.gov/pubmed/31852136 http://dx.doi.org/10.1097/MD.0000000000018351 |
work_keys_str_mv | AT leedohyeong riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate AT yunbyungcheol riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate AT seokwangil riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate AT hanbyunghoon riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate AT leesanguk riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate AT parkeuntaek riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate AT leejinwook riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate AT jeongjoonho riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate |